絞り込み

16544

広告

Clinical Predictors of Extrapyramidal Symptoms Associated With Aripiprazole Augmentation for the Treatment of Late-Life Depression in a Randomized Controlled Trial.

著者 Hsu JH , Mulsant BH , Lenze EJ , Sanches M , Karp JF , Reynolds CF , Blumberger DM
J Clin Psychiatry.2018 Jun 19 ; 79(4):.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (26view , 0users)

Medical

Miscellaneous

Augmentation with aripiprazole is an effective pharmacotherapy for treatment-resistant late-life depression (LLD). However, aripiprazole can cause extrapyramidal symptoms (EPS) such as akathisia and parkinsonism; these symptoms are distressing and can contribute to treatment discontinuation. We investigated the clinical trajectories and predictors of akathisia and parkinsonism in older patients receiving aripiprazole augmentation for treatment-resistant LLD.
PMID: 29924506 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード